REGULATED INFORMATION
Paris, January 20, 2022 – 7 p.m. CET –
In accordance with the provisions of Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers:
|
Dated |
Number of shares making up the capital |
Number of GROSS voting rights |
Number of NET voting rights |
31/12/2021 | 19,910,524,274 | 19 912 759 024 | 19,911,304,155 |
In addition, the company recalls that, since the implementation of the various financing contracts, the number of shares issued each month by the company breaks down as follows:
|
Wording |
ORNANE |
OCEANE-BSA |
Total |
Aug-20 | 1 111 111 | 1,875,000 | 2,986,111 |
Sep-20 | 14,583,330 | 18,747,124 | 33 330 454 |
Oct-20 | 7,250,000 | 47,956,900 | 55,206,900 |
Nov-20 | 33 333 333 | 128,752,699 | 162 086 032 |
Dec-20 | 50,000,000 | 190,000,000 | 240,000,000 |
Jan-21 | 42,500,000 | 150,000,000 | 192,500,000 |
Feb-21 | 90,000,000 | 215,000,000 | 305,000,000 |
March-21 | 10,000,000 | 180,000,000 | 190,000,000 |
April-21 | 120,000,000 | 120,000,000 | |
May-21 | 892 222 214 | 892 222 214 | |
Jun-21 | 1,186,944,432 | 1,186,944,432 | |
July-21 | 1,074,999,998 | 1,074,999,998 | |
Aug-21 | 1,300,000,000 | 1,300,000,000 | |
Sep-21 | 1,158,302,986 | 1,158,302,986 | |
Oct-21 | 4,243,938,060 | 4,243,938,060 | |
Nov-21 | 8,571,425,000 | 8,571,425,000 | |
Dec-21 | 0 | 0 |
As a reminder, the permanent monitoring of the creation of new shares resulting in particular from conversions of OCEANEs is the subject of a summary table that is systematically updated and available on the NEOVACS website.
ABOUT NEOVACS
Neovacs is a French biotechnology company, listed on Euronext Growth since 2010, specializing in therapeutic vaccines targeting the treatment of autoimmune diseases. Its innovative technology called Kinoid®, patented until 2038, makes it possible to induce a polyclonal immune response, applicable in several indications. Neovacs has developed IFNα Kinoid for the treatment of lupus in a phase IIb clinical study. The main study has been completed, the full results were presented on the 13
th
2019 international lupus congress. The Company has also completed promising preclinical work with another therapeutic vaccine, IL-4/IL-13 Kinoid, for the treatment of allergies. The ambition of this “Kinoid® approach” is to enable patients to better tolerate a lifelong treatment which would be more effective, well tolerated and very flexible in its administration.
For more information :
www.neovacs.fr
Jérôme FABREGUETTES-LEIB | Deborah SCHWARTZ |
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
yW1ukZ2bk2aXnHBrZZuWnGaYbGxilmGdm2HHyZVpmJ3Ibm2Tlmhpb8WVZnBjnWdu
– To check this key:
https://www.security-master-key.com.
Regulated information:
Total number of voting rights and capital:
– Information relating to the total number of voting rights and shares making up the capital
Full and original press release in PDF format:
https://www.actusnews.com/news/72828-2021.12.31_nvcs_cp_ddv_decembre-2021.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com